Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 114

Sort by

Sort Order Select

Journal Articles

Single Cell Immune Profiling of Colitogenic T Cells during Acute Graft Versus Host Disease Reveals Two Novel Transcriptionally Distinct CD4+ GM-CSF+ Lineages

Clinton Piper, BS, Achia Khatun, BS, Yao Chen, BS, Ryan Zander, PhD, Weiguo Cui, MD PhD, William R. Drobyski, MD

Blood (2019) 134 (Supplement_1): 197.

https://doi.org/10.1182/blood-2019-127095

Published: 2019

Journal Articles

Phase 1/2 Study of AUTO3 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study

Kirit M. Ardeshna, MBBChir, Maria A V Marzolini, Jane Norman, MD, Muhammad Al-Hajj, Simon Thomas, PhD, Jim Faulkner, Ekaterini Kotsopoulou, Martin Pule, MD, Vijay G R Peddareddigari, Nushmia Z Khokhar, Maud Jonnaert, PhD, Robert Chen, MD, Wendy Osborne, MD

Blood (2019) 134 (Supplement_1): 246.

https://doi.org/10.1182/blood-2019-122724

Published: 2019

Journal Articles

Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma

Kenta Mukaihara, MD PhD, Mattia D'Agostino, MD, Cristina Panaroni, PhD, Keertik Fulzele, PhD, Tomoaki Mori, MD PhD, Ka Tat Siu, PhD, Shrikanta Chattopadhyay, MBBS, Noopur Raje, MD

Blood (2019) 134 (Supplement_1): 4382.

https://doi.org/10.1182/blood-2019-130462

Published: 2019

Journal Articles

Tumor Microenvironment Differs between Germinal Centre B-Cell and Non-Germinal Centre B-Cell like Diffuse Large B-Cell Lymphomas and Has Subtype-Specific Prognostic Impact on Survival

Matias Autio, Suvi-Katri Leivonen, PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Teijo Pellinen, PhD, Sirpa Leppa, MD PhD

Blood (2019) 134 (Supplement_1): 5230.

https://doi.org/10.1182/blood-2019-129681

Published: 2019

Journal Articles

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Induces T-Cell-Mediated Killing in Relapsed or Refractory Non-Hodgkin Lymphoma: Biomarker Results From a Phase I Dose-Escalation Trial

Ann-Marie E Bröske, PhD, Ian James, PhD, Anton Belousov, PhD, Enrique Gomez, PhD, Marta Canamero, MD PhD, Chia-Huey Ooi, PhD, Nils Grabole, PhD, Sabine Wilson, PhD, Koorosh Korfi, PhD, Nicole A Kratochwil, PhD, Peter N Morcos, PharmD, Cristiano Ferlini, MD, Denise Thomas, MSc, Natalie Dimier, PhD, Tom Moore, MBChB, Marina Bacac, PhD, Martin Weisser, MD, Michael Dickinson, MBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 5319.

https://doi.org/10.1182/blood-2019-123979

Published: 2019

Journal Articles

Elotuzumab Enhances the Th2-Mediated Immune Response of Dendritic Cell Induced By Immunomodulatory Drugs (IMiDs)

Yoshiko Azuma, MD, Tomoki Ito, MD PhD, Muneo Inaba, PhD, Kai Imai, MD, Masaaki Hotta, MD, Atsushi Satake, MD PhD, Shosaku Nomura, MD PhD

Blood (2019) 134 (Supplement_1): 4342.

https://doi.org/10.1182/blood-2019-129680

Published: 2019

Journal Articles

Cross Talk between the Immune Compartment and the Tumor Cells in Myelodysplastic Syndromes (MDS)

Camille Bigenwald, MD, Amir Horowitz, PhD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Richa Rai, PhD, Stella Melana, PhD, Erin P. Demakos, RN, Miriam Merad, MD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 2986.

https://doi.org/10.1182/blood-2019-124887

Published: 2019

Journal Articles

Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells

Nadia El Khawanky, Bsc(Biomed), BHlthSc(Hons), Amy Hughes, PhD, Wenbo Yu, PhD, Sanaz Taromi, PhD, Jade Clarson, BSc, Angel F. Lopez, MD PhD, Michael P. Brown, MD PhD, Justus Duyster, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Deborah L. White, PhD FFSc (RCPA), Agnes S. M. Yong, MD PhD, Robert Zeiser, MD

Blood (2019) 134 (Supplement_1): 3904.

https://doi.org/10.1182/blood-2019-124684

Published: 2019

Journal Articles

Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy Targeting CD19 and CD22, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study

Persis J Amrolia, FRCP, FRCPath, PhD, Robert Wynn, MD, Rachael E Hough, MD, Ajay Vora, Denise Bonney, Paul Veys, MD PhD, Robert Chiesa, Kanchan Rao, Liz Clark, Muhammad Al-Hajj, Shaun P Cordoba, PhD, Shimobi Onuoha, PhD, Ekaterini Kotsopoulou, Nushmia Z Khokhar, Martin Pule, MD, Vijay G R Peddareddigari

Blood (2019) 134 (Supplement_1): 2620.

https://doi.org/10.1182/blood-2019-123424

Published: 2019

Journal Articles

Mechanisms of Tolerance Induction through T Regulatory Cells during Chemotherapy-Mediated Immunogenic Cell Death in Acute Myeloid Leukemia

Darina Ocadlikova, PhD, Serenella Casella, Ines Pintao, Elena Adinolfi, Sabina Sangaletti, PhD, Elena De Marchi, Anna Pegoraro, Elisa Orioli, Mario Paolo Colombo, Francesco Di Virgilio, Michele Cavo, Antonio Curti, MD PhD

Blood (2019) 134 (Supplement_1): 2332.

https://doi.org/10.1182/blood-2019-126478

Published: 2019

Journal Articles

Combined Infusion of Anti-CD19 and Anti-Bcma CART Cells after Early or Later Transplantation in the Front Line Was Superior to Salvage Therapy for High Risk MM

Blood (2019) 134 (Supplement_1): 1949.

https://doi.org/10.1182/blood-2019-131546

Published: 2019

Journal Articles

A New Promising Third Generation CAR-CD30 T-Cell Therapy for CD30+ Lymphoma

Blood (2019) 134 (Supplement_1): 2069.

https://doi.org/10.1182/blood-2019-127969

Published: 2019

Journal Articles

Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia

Lina Driouk, MD, Joanina Gicobi, Yusuke Kamihara, MD PhD, Kayleigh Rutherford, Glenn Dranoff, MD, Jerome Ritz, MD, Susanne H.C. Baumeister, MD

Blood (2019) 134 (Supplement_1): 1930.

https://doi.org/10.1182/blood-2019-130113

Published: 2019

Journal Articles

Tandem CAR T Cells Targeting CD19 and CD22 Is a Safe and Highly Efficacious Treatment for Relapse/ Refractory ALL Patients

Xiaowen Tang, Liqing Kang, Wei Qi, Wei Cui, Haiping Dai, Zheng Li, Jia Yin, Changju Qu, PhD, Ting Xu, Xiaming Zhu, Lei Yu, MD PhD, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 1338.

https://doi.org/10.1182/blood-2019-127890

Published: 2019

Journal Articles

Single-Cell Mass Cytometry Identifies Mechanisms of Resistance to Immunotherapy in AML

Shelley Herbrich, MS, Antonio Cavazos, Cora Marie C Cheung, BSN, Lynette Alexander-Williams, Nicholas J. Short, MD, Jairo Matthews, Naval G. Daver, MD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 1428.

https://doi.org/10.1182/blood-2019-128601

Published: 2019

Journal Articles

Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)

Paul G. Richardson, MD, Swethajit Biswas, Beata Holkova, Nicola Jackson, Thelma Netherway, Weichao Bao, Geraldine Ferron-Brady, Anne Yeakey, Chris Shelton, Rocio Montes De Oca, PhD, Chris Ahlers, Sonia Franco, Marc Ballas, Elaine Paul, Katarina Luptakova, Ira Gupta, Joanna Opalinska

Blood (2019) 134 (Supplement_1): 1857.

https://doi.org/10.1182/blood-2019-129879

Published: 2019

Journal Articles

Phase 1 First-in-Human Study of AUTO2, the First Chimeric Antigen Receptor (CAR) T Cell Targeting APRIL for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Rakesh Popat, Sonja Zweegman, MD PhD, Jim Cavet, FRCPath, Kwee Yong, Lydia Lee, Jim Faulkner, Ekaterini Kotsopoulou, Muhammad Al-Hajj, Simon Thomas, PhD, Shaun P Cordoba, PhD, Martin Pule, MD, Virginie Cerec, PhD, Vijay G R Peddareddigari, Nushmia Z Khokhar, MD, Tobias F Menne, MD PhD FRCPath

Blood (2019) 134 (Supplement_1): 3112.

https://doi.org/10.1182/blood-2019-126689

Published: 2019

Journal Articles

Tracking T Cell Activation By OX40 Immuno-PET: A Novel Strategy for Imaging of Graft Versus Host Disease

Federico Simonetta, MD PhD, Israt S. Alam, PhD, Aaron T. Mayer, Surya Murty, Ophir Vermesh, MD PhD, Toshihito Hirai, MD PhD, Tomomi Nobashi, MD, Kenneth Lau, Sanjiv S. Gambhir, MD PhD, Robert S. Negrin, MD

Blood (2018) 132 (Supplement 1): 4527.

https://doi.org/10.1182/blood-2018-99-116483

Published: 2018

Journal Articles

Uncovering the Molecular Signature of Pathogenic Tissue-Infiltrating T Cells during Acute Graft-Versus-Host Disease

Victor Tkachev, PhD, Scott N Furlan, MD, E. Lake Potter, Hengqi Zheng, MD, Daniel J Hunt, Lucrezia Colonna, PhD, Agne Taraseviciute, MD PhD, Judith M Carlson, BS, Kayla Betz, Alison Yu, PhD, Michelle Hoffman, MS, Audrey Baldessari, DVM, Sarah Herrin, Joe Olvera, Chad Littlewood, Christopher English, Bruce R. Blazar, MD, Mario Roederer, PhD, Leslie Kean, MD PhD

Blood (2018) 132 (Supplement 1): 805.

https://doi.org/10.1182/blood-2018-99-113652

Published: 2018

Journal Articles

Quantitative Multiplex Immunohistochemistry Identifies Immunosuppression in the AML Bone Marrow and NK-Cells As Prognostic Biomarker in Intermediate-Risk Patients

Oscar Brück, MD, Olli Dufva, Sami Blom, MSc, Riku Turkki, MSc, Mette Ilander, PhD, Sanna M. Siitonen, MD PhD, Panu Kovanen, MD PhD, Celine Pallaud, PhD, Pedro Marques Ramos, PhD, Hanna Lähteenmäki, Katja Välimäki, Antonio Ribeiro, BSc, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Teijo Pellinen, PhD, Satu Mustjoki, MD PhD

Blood (2018) 132 (Supplement 1): 2774.

https://doi.org/10.1182/blood-2018-99-116628

Published: 2018

NARROW

Single Cell Immune Profiling of Colitogenic T Cells during Acute Graft Versus Host Disease Reveals Two Novel Transcriptionally Distinct CD4+ GM-CSF+ Lineages

Phase 1/2 Study of AUTO3 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study

Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma

Tumor Microenvironment Differs between Germinal Centre B-Cell and Non-Germinal Centre B-Cell like Diffuse Large B-Cell Lymphomas and Has Subtype-Specific Prognostic Impact on Survival

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Induces T-Cell-Mediated Killing in Relapsed or Refractory Non-Hodgkin Lymphoma: Biomarker Results From a Phase I Dose-Escalation Trial

Elotuzumab Enhances the Th2-Mediated Immune Response of Dendritic Cell Induced By Immunomodulatory Drugs (IMiDs)

Cross Talk between the Immune Compartment and the Tumor Cells in Myelodysplastic Syndromes (MDS)

Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells

Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy Targeting CD19 and CD22, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study

Mechanisms of Tolerance Induction through T Regulatory Cells during Chemotherapy-Mediated Immunogenic Cell Death in Acute Myeloid Leukemia

Combined Infusion of Anti-CD19 and Anti-Bcma CART Cells after Early or Later Transplantation in the Front Line Was Superior to Salvage Therapy for High Risk MM

A New Promising Third Generation CAR-CD30 T-Cell Therapy for CD30+ Lymphoma

Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia

Tandem CAR T Cells Targeting CD19 and CD22 Is a Safe and Highly Efficacious Treatment for Relapse/ Refractory ALL Patients

Single-Cell Mass Cytometry Identifies Mechanisms of Resistance to Immunotherapy in AML

Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)

Phase 1 First-in-Human Study of AUTO2, the First Chimeric Antigen Receptor (CAR) T Cell Targeting APRIL for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Tracking T Cell Activation By OX40 Immuno-PET: A Novel Strategy for Imaging of Graft Versus Host Disease

Uncovering the Molecular Signature of Pathogenic Tissue-Infiltrating T Cells during Acute Graft-Versus-Host Disease

Quantitative Multiplex Immunohistochemistry Identifies Immunosuppression in the AML Bone Marrow and NK-Cells As Prognostic Biomarker in Intermediate-Risk Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only